BIOLINERX     Print Page  Close Window

SEC filings
SC 13G/A
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP filed this Form SC 13G/A on 02/16/2016
Entire Document
 



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)*



 

BioLineRx Ltd.
(Name of Issuer)

 

 

Ordinary Shares, NIS 0.01 par value
(Title of Class of Securities)

 

 

09071M106
(CUSIP Number)

 

 

December 31, 2015
(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 2 of 8 Pages
         
1
NAME OF REPORTING PERSONS
 
OrbiMed Israel BioFund GP Limited Partnership
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
2,638,600 (1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
2,638,600 (1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,638,600 (1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
4.69% (2)
12
TYPE OF REPORTING PERSON
 
PN
(1) Evidenced by 1,038,600 American Depositary Shares ("ADS") (each ADS represents one Ordinary Shares (as defined below)) and 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs (the "Warrants") held by OrbiMed Partners (as defined below).
(2) This percentage is based upon 54,654,811 Ordinary Shares outstanding as of October 15, 2015, as disclosed in the Issuer's Form F-3 filed with the Securities and Exchange Commission on October 16, 2015, and includes 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs.
 

CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 3 of 8 Pages
         
1
NAME OF REPORTING PERSONS
 
OrbiMed Israel GP Ltd.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
2,638,600 (1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
2,638,600 (1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,638,600 (1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
4.69% (2)
12
TYPE OF REPORTING PERSON
 
CO
(1) Evidenced by 1,038,600 American Depositary Shares ("ADS") (each ADS represents one Ordinary Shares (as defined below)) and 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs (the "Warrants") held by OrbiMed Partners (as defined below).
(2) This percentage is based upon 54,654,811 Ordinary Shares outstanding as of October 15, 2015, as disclosed in the Issuer's Form F-3 filed with the Securities and Exchange Commission on October 16, 2015, and includes 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs.
 

 

CUSIP No.  09071M106
 SCHEDULE 13G/A
Page 4 of 8 Pages

 

Item 1.(a) Name of Issuer:

BioLineRx Ltd.

(b) Address of Issuer’s Principal Executive Offices:

2 HaMa’ayan Street

Modi’in 7177871, Israel

Item 2.(a) Name of Person Filing:

This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”):

(i)  OrbiMed Israel BioFund GP Limited Partnership (“OrbiMed BioFund”); and

(ii) OrbiMed Israel GP Ltd. (“OrbiMed Israel”).

See Exhibit A for the Reporting Persons’ agreement for a joint filing of a single statement on their behalf.

(b) Address of Principal Business Office:

The address of the principal business office of each of OrbiMed BioFund and OrbiMed Israel is 89 Medinat HaYehudim St., Build E, 11th Floor, Herzliya 46766, Israel.

(c) Citizenship:

Each Reporting Person was organized under the laws of the State of Israel

 (d) Title of Class of Securities:

Ordinary Shares, NIS 0.01 par value (the “Ordinary Shares”)

 (e) CUSIP No.:

09071M106

 
 

 

CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 5 of 8 Pages

 

Item 3.

Not Applicable

 
 

 

CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 6 of 8 Pages

 

 

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

OrbiMed Israel is the general partner of OrbiMed BioFund, which is the general partner of OrbiMed Israel Partners Limited Partnership, an Israel limited partnership (“OrbiMed Partners”), which holds the ADSs and Warrants. OrbiMed Israel, as the general partner of OrbiMed BioFund, and OrbiMed BioFund, as the general partner of OrbiMed Partners, may be deemed to share voting and investment power with respect to the Ordinary Shares underlying the ADSs and Warrants held by OrbiMed Partners.

(a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).

(b) Percent of class: See the response(s) to Item 11 on the attached cover page(s).

(c) Number of shares as to which the person has:

(i)  Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).

(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).

(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).

(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of Five Percent or Less of a Class.

If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 
 
CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 7 of 8 Pages

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 16, 2016

 

 

 

       
  ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP
       
  By: OrbiMed Israel GP Ltd., its General Partner
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title: Director
       
  ORBIMED ISRAEL GP LTD.
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title:  Director

 

 
 
CUSIP No.  09071M106
 SCHEDULE 13G/A
Page 8 of 8 Pages

 

 

EXHIBIT A

JOINT FILING AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendment thereto, with respect to the beneficial ownership by each of the undersigned of the Ordinary Shares of BioLineRx Ltd. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 16, 2016.

 

 

       
  ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP
       
  By: OrbiMed Israel GP Ltd., its General Partner
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title: Director
       
  ORBIMED ISRAEL GP LTD.
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title:  Director